Timm Medical Broadens Incontinence Portfolio With UroSurge Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Timm Medical Technologies plans to proceed with clinical trials of UroSurge's implantable SANS stoller afferent nerve stimulation device for treatment of urinary incontinence if its acquisition of UroSurge closes May 31 as planned. Financial terms of the deal were not disclosed.
You may also be interested in...
Medtronic Building InterStim Registry; Data Show Early Treatment Benefit
Medtronic is assembling a patient registry for the InterStim urinary incontinence sacral nerve stimulation device that will offer insight into current best practices for device application and quality of life.
UroSurge Urinary Incontinence Device To Hit U.S. Market In Next 2 Weeks
UroSurge says it will launch the Percutaneous Stoller Afferent Nerve Stimulation (SANS) system in the next two weeks for symptomatic treatment of urinary urgency, frequency or urge incontinence. FDA cleared the device Feb. 9 via a de novo 510(k) with clinical trials as a special control.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.